Bernard FROMENTY, DR
Expertise in hepatotoxicity induced by xenobiotics including ethanol and drugs, in particular in the context of obesity and nonalcoholic fatty liver disease (NAFLD).
Research topics and scientific objectives
The main objectives of my research is to determine the mechanisms of hepatotoxity induced by different xenobiotics including ethanol and drugs such as amiodarone and acetaminophen (APAP). The role of mitochondrial dysfunction and oxidative stress is more specifically studied.
In addition, my investigations try to decipher the mechanisms whereby some xenobiotics such ethanol and APAP are more toxic in the context of obesity and nonalcoholic fatty liver disease (NAFLD). The cytochrome P450 2E1 (CYP2E1) is particularly investigated in these studies since the activity of this enzyme is enhanced during NAFLD, thus increasing the generation of toxic reactive metabolites.
Education and main positions held
1990: Doctorate in Pharmacy (University of Paris 5).
1991: PhD in Pharmacology (University of Paris 6).
1999: Accreditation to Supervise Research (HDR-University of Paris 7).
1996: Recruited by INSERM as Research Assistant (CR1).
2006: Promoted to the rank of Director of Research (DR2).
2006-2009: Leader of Team n°5 (Mitochondria and liver), INSERM Unit 773 (Centre de Recherche Biomédicale Bichat-Beaujon-CRB3 – Paris; Head: Marc Laburthe).
2010-2016: Leader of Team n°3 (Hepatotoxicity of xenobiotics: mechanisms and modulation by obesity), INSERM Unit 991 (Liver, Metabolisms and Cancer- Rennes; Head: Bruno Clément).
Several projects pertaining to the toxic effects of different xenobiotics (drugs, ethanol and environmental contaminants) in normal and steatotic HepaRG cells and/or in lean and obese mice.